Angle Share Discussion Threads

[john henry] 29/1/2024 11:20

Price action would maybe still indicate an Institutional holder has decided to dump a few today. Price back in the gap buying zone.
May this time test the bottom of the gap at 14p

[atmysignal] 29/1/2024 11:00

Who actually cares?

[robizm] 29/1/2024 10:00

Sawney he ramps on LSE telling people it is a good time to buy whilst he sells. I had better read the dictionary definition of a ramper.

[sawney] 29/1/2024 09:24

He's been pretty open about what he's doing and I certainly wouldn't regard it as ramping....

[robizm] 29/1/2024 09:18

Put him on filter. Dave is a trader trying to sucker people in then dump. I don’t know anyone who spends all day on level 4 monitoring a illiquid share unless you are trading to make pennies profit.

[sawney] 29/1/2024 09:06

Can I suggest that anyone who genuinely has something original/interesting to say on AGL...now post on the moderated board thus leaving Bonehead99 and his mates to their own echo chamber...Nobody minds a bit of constructive criticism but Bonehead99 spamming his repetitive drivel is just a waste of space...

[bones699] 29/1/2024 08:50

"Thanks for the buying opportunity again I'll make another killing here soon"

No problem you paid for it!

Yes I've made a fortune here ramping the stock then shorting the f@@k out of it but pls don't tell the missus!

Fake bones seems disgruntled maybe his new job is getting him down watching paint dry at 14p or is it 40p seems he held the stock for donkeys years but now says he offloaded recently!

Made loads of money 💰 yeh right lol!

I will remind you nearer to 4p lol

[adw198] 29/1/2024 07:28

Oh right you value the company at whatever cash is in the bank, literally nothing more, nothing less? And that’s presumably how you value all the other companies you’re invested in too?

If so, yes that’s very helpful / insightful as to who I’m talking to.

[bones699] 29/1/2024 06:15

Adw198

I actually quoted.

"at what share price 12p or much less by the look of things.."

On a cash basis 257m shares cash c.£12m 4.6p but until we find out the Dec 2023 closing cash position this is yet unclear. June 2023 was £22m but monthly cash burn c.£1m?

Hope that helps!

[spa362] 28/1/2024 21:09

Lol great post Adw198
Share was 10-12p before recent breakthrough
Upside far more likely than downside therefore - it's just the way of things!
I think Monday will be quite blue

[adw198] 28/1/2024 20:23

@bones669 can I ask where your 12p valuation comes from? You appear fixated on the current loss making position and dismissive of the future prospects. Perfectly reasonable views, but in that case what’s the rationale behind 12p as opposed to say 2, 4, 8, 16 or 32p?

Whilst I would normally rail against cross ramping, given your somewhat obsessive posting here as a non investor, could you outline the stocks you’re currently invested in and averages there. Would be interested to see how the rationale is applied elsewhere, along with your success.

And finally, shall we have a gentleman’s bet about what this hits first - your 12p valuation, or 5.5p the other (current) way of 23p. Loser agrees never to post here again other than to acknowledge they got wrong?

[bones699] 28/1/2024 12:37

Htrocka2

Not sure your point Global Frontiers added 1% so what hardly material any new ii's to add?...I can't see any new TR1 notices.

Broom23

The other Bones698 is the one watching paint dry here as he is the fake one bragging about how AGL was really taking off and ranping it but in reality the real bones knows better if the financial fundamentals don't add up always best to keep a level head and not get drawn in though empty bluster from the gerbil ramping camp..Fake Bones698 claims his average holding is 14p after already stating it was 40p on another thread and comes across just as a ramping day trader!

[broom23] 28/1/2024 11:00

Bones699 - how many bones are on this chat, I read conflicting posts.

Admittedly clearance was made on 24 May 2022, but it was only recently that pertinent clinical trial data was posted which shows quite clearly the advantages of the device in determining the most suitable breast cancer treating drugs to utilise for a given patient.

Agreed, there are many other forms of cancer but the move towards blood assay, rather than physical sample biopsy, is getting more evident every year. This is relatively new ground in the grand scheme of things and Angle are well down that road with ‘in house’ expertise and patent.

Many life science companies struggle with cash flow issues, especially at the outset. The rewards for perseverance can be immeasurable. Big Pharma, as you put it, spend vast sums developing new drugs, with no revenue from them until many years down the road.

[htrocka2] 28/1/2024 09:27

bones699.....There are some people that actually enjoy your posts....and take advantage of them....by increasing their holdings.(are these the people you're working for?)

[bones699] 28/1/2024 09:10

So let's talk about financial fundamentals here shall we rather than day dreaming chasing vanishing rainbows over the horizon. 🌈 🤔.

Now Parsortix has been cleared for nearly two years and there is around 24 main cancer types of which only one has been approved by the FDA for testing breast cancer using the Parsortix machine.

So here is the conundrum not only has AGL generated virtually no sales revenues in two years despite having approval for breast cancer treatment but to generate sales it is unwilling to complete the testing required for the remaining 23 cancer types expecting the third party labs to do this themselves.

Well it doesn't take a rocket scientist to figure out that to date LabCorp and Quest Diagnostics the two USA leading lab company's has shown next to no interest in buying Parsortix machines due no doubt to the severe limitation in cancer testing.

Hence Newlands claim at the recent Investor Meet that third party labs are likely to take on Parsortix and seek their own accreditation because that is exactly what he was alluding too appear unfounded!

As to date non of the big USA lab chains have done what Newland claimed they would do in nearly two years since FDA clearance!...

We can now see that the financial fundamentals are beginning to fall apart, low cash balances c.£12m at best, a high monthly cash burn rate over £1.4m and Newland claiming that an additional £6m revenues will occur out of apparently thin air only reference at the Investor Meet by their CFO looking quite twitcher I might add when asked about the cash runway was funding would be from 'strategic opportunities' and 'project milestones' whatever that was meant to mean before alluding to tapping the market as in the past, just gave the game away don't you think!

So there we have the crux of the matter a business running out of both time and money before the next eventual cash raise.

Meanwhile the market has now cottoned on to Newlands tricks ramping RNS releases all of which lack financials and timelines with the seeming sole objective to keep the share price up ahead of a potential cash raise to mitigate the size and scale of yet another damaging £20m share issuance, to chuck onto the pile of burnt investor cash over £130m to date, and at what share price 12p or much less by the look of things..

Meanwhile other competitors are entering the market space and closer to full FDA approval than AGL while 'BIG PHARMA' could have picked AGL up for under 10p and show no interest, no surprises there then!

AGL should carry a government health warning that these 🌈's are never free and can and do fade over time!

[bones699] 27/1/2024 19:45

I expect the share price to continue correcting to sub 12p £42m is a ridiclous market cap for a loss making high cash burn aim listed firm generating next to nothing in revenues..As for a take over lol why didn't 'BIG PHARMA' whoever they are make a bid when the share price was under 10p they didn't did they despite the fact that the Parsortix machine received FDA clearance two years ago..what does that tell you!

[broom23] 27/1/2024 12:31

@5oletrader. Interesting post but your Regulatory comments on TRINETRA are a bit back to front. A PMA (premarket approval) is only required for class III devices. A 510k submission is only made when there is predicate device (substantially equivalent) already in the market place. The De Novo process is used for unclassified devices for which there is no predicate device and is not likely to be considered high risk (Class III).

The Angle harvesting device is cleared as a class II, as would any other generic device proposed.

There is a lot of interest being generated, especially after the clinical data posting- which you deem irrelevant, I think?

Although a standalone device, it is being marketed for obvious use with CTC DNA analysers. The big players will note this. Angel could well be targeted for a takeover. We could possibly see some Shorting of the stock to keep share price down until a serious move is made on uptake - which of course would need to be divulged. Time will tell but this is an interesting product, in line with current trend in liquid assay as opposed to biopsy.